Jean and others--for certain bc subtypes size and no. of lymph nodes , prognosis not

[Lani]

that whether size, lymph node status portended worse prognosis differed between her2+er+ and her2+ er- , but they only had 60 of the later and 107 of the former. (perhaps not enough to draw conclusions).

Bottom-line is that classical determinants of prognosis are undergoing reevaluation especially as we start realizing the subtypes of bc are different diseases with different behaviors.

Recommendations for treatment should be getting more and more individualized and less cookie-cutter like as molecular subtyping becomes more common.

Less hope this leads to more people getting just the treatment most likely to help them and lessens both over and undertreatment.